11.56
1.85%
0.21
Rocket Pharmaceuticals Inc stock is traded at $11.56, with a volume of 2.37M.
It is up +1.85% in the last 24 hours and down -11.35% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
See More
Previous Close:
$11.35
Open:
$11.31
24h Volume:
2.37M
Relative Volume:
2.26
Market Cap:
$1.23B
Revenue:
-
Net Income/Loss:
$-249.31M
P/E Ratio:
-3.4924
EPS:
-3.31
Net Cash Flow:
$-209.70M
1W Performance:
-3.83%
1M Performance:
-11.35%
6M Performance:
-44.56%
1Y Performance:
-58.57%
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
11.56 | 1.23B | 0 | -249.31M | -209.70M | -2.87 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-18-24 | Initiated | Jefferies | Buy |
Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
Apr-02-24 | Initiated | Goldman | Neutral |
Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
Feb-01-23 | Initiated | Morgan Stanley | Overweight |
Nov-08-22 | Initiated | Canaccord Genuity | Buy |
Nov-01-22 | Initiated | BTIG Research | Buy |
Jul-08-22 | Initiated | Raymond James | Outperform |
Oct-20-21 | Resumed | Cowen | Outperform |
Mar-02-21 | Initiated | Stifel | Buy |
Feb-18-21 | Initiated | Needham | Buy |
Dec-16-20 | Initiated | UBS | Buy |
Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
Jul-02-20 | Initiated | JP Morgan | Overweight |
Jun-25-20 | Resumed | BofA/Merrill | Buy |
Jun-01-20 | Resumed | Oppenheimer | Outperform |
Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
Sep-26-19 | Initiated | Piper Jaffray | Overweight |
Apr-23-19 | Initiated | Robert W. Baird | Outperform |
Mar-15-19 | Initiated | BofA/Merrill | Buy |
Feb-05-19 | Initiated | Oppenheimer | Outperform |
Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy' - MSN
Rocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 1-Year LowWhat's Next? - MarketBeat
State Street Corp Buys 322,156 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Franklin Resources Inc. Cuts Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
State Street Corp Has $57.29 Million Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap UpWhat's Next? - MarketBeat
Jefferies Financial Group Initiates Coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) - MarketBeat
Head-To-Head Review: InMed Pharmaceuticals (NASDAQ:INM) & Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
RTW INVESTMENTS, LP Increases Stake in Rocket Pharmaceuticals Inc - GuruFocus.com
(RCKT) Trading Report - Stock Traders Daily
Synovus Financial Corp Decreases Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Leerink Partnrs Has Positive Outlook of RCKT FY2024 Earnings - MarketBeat
FY2024 Earnings Estimate for RCKT Issued By Leerink Partnrs - Defense World
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com Australia
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals (NASDAQ:RCKT) Hits New 1-Year LowHere's What Happened - MarketBeat
Rocket Pharmaceuticals completes $178.1 million offering - Investing.com India
Rocket Pharmaceuticals completes $178.1 million offering By Investing.com - Investing.com Australia
RSI Alert: Rocket Pharmaceuticals (RCKT) Now Oversold - Nasdaq
RCKT Stock Hits 52-Week Low at $12.62 Amid Market Challenges - Investing.com India
RCKT Stock Hits 52-Week Low at $12.62 Amid Market Challenges By Investing.com - Investing.com South Africa
Fmr LLC Lowers Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals sets $12.50 share price for offering By Investing.com - Investing.com South Africa
Watkins Advises on Rocket Pharmaceuticals’ Upsized Public Offering of Common Stock - Latham & Watkins LLP
Rocket Pharmaceuticals sets $12.50 share price for offering - Investing.com India
Rocket Pharmaceuticals Secures $165M Through Upsized Public Stock Offering at $12.50 Per Share - StockTitan
Rocket Pharmaceuticals plans $150 million stock offering By Investing.com - Investing.com Canada
Point72 Asset Management L.P. Acquires Shares of 48,096 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals plans $150 million stock offering - Investing.com India
Rocket Pharmaceuticals Plans $150 Million Public Offering of Common Shares - Marketscreener.com
Rocket Pharmaceuticals Launches $150M Public Offering to Advance Genetic Therapy Pipeline - StockTitan
Frazier Life Sciences Management L.P. Sells 75,600 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Wellington Management Group LLP Acquires 2,086,424 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Janus Henderson Group PLC Has $35.06 Million Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
(RCKT) Investment Report - Stock Traders Daily
44,700 Shares in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Purchased by Erste Asset Management GmbH - MarketBeat
Walleye Capital LLC Buys New Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Rocket Pharmaceuticals Offers Huge Potential as Price Targets Exceed 300% Growth - TheStreet
Bamco Inc. NY Sells 94,990 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain (RCKT) - Seeking Alpha
RCKT (Rocket Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Nov. 30, 2024) - GuruFocus.com
RCKT (Rocket Pharmaceuticals) Cash From Other Investing Act - GuruFocus.com
RCKT (Rocket Pharmaceuticals) PE Ratio without NRI : At Loss (As of Nov. 29, 2024) - GuruFocus.com
RCKT (Rocket Pharmaceuticals) Cash, Cash Equivalents, Marke - GuruFocus.com
RCKT (Rocket Pharmaceuticals) Price-to-Free-Cash-Flow : N/A (As of Nov. 28, 2024) - GuruFocus.com
RCKT (Rocket Pharmaceuticals) 50-Day SMA : $16.76 (As of Nov. 28, 2024) - GuruFocus.com
Acuta Capital Partners LLC Sells 60,370 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
3 Small-Cap Stocks That Are Ready to Rocket Higher - sharewise
Fiverr International Ltd (FVRR-N) QuotePress Release - The Globe and Mail
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):